In one recent study of racial differences in AD biomarkers (Morris et al., 2019), Black/African American participants had lower levels of CSF total tau and phosphorylated tau compared to White participants, with stronger differences in Black/African Americans with the APOE4 genotype. This evidence concerns the gene MAPT and Alzheimer disease.